Ind-Swift Laboratories Ltd to commercially launch key API - Fexofenadine

Ind-Swift Laboratories Limited is all set to commercially launch its key API - Fexofenadine, an AntiHistamine Drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market.

The Company has tied up with a reputed generic player in USA, which had filed the ANDA using the IndSwift Laboratories Limited DMF. The Company has received the commercial orders and the supplies are beginning from the current quarter.

USA is a significant market for this product. Over 14% of the total turnover of the Company is contributed by the US market. The Company supplies 7-8 products commercially to the US market. The Company has been successfully inspected by the USFDA in March 2020 for the sixth time since its inception, without any 483 observations. The Company has also received EIR.

Shares of IND-SWIFT LABORATORIES LTD. was last trading in BSE at Rs.30.45 as compared to the previous close of Rs. 30.05. The total number of shares traded during the day was 2134 in over 60 trades.

The stock hit an intraday high of Rs. 31.75 and intraday low of 29. The net turnover during the day was Rs. 63987.

Source : Equity Bulls

Keywords